Just four months after ending an 18-year stint as chief executive of BioMarin, Jean-Jacques Bienaimé, has been named chairman of Owkin, a specialist in applying artificial
Basecamp Research says it has augmented the AlphaFold2 artificial intelligence tool for predicting protein structures to create a platform that is more accurate and better
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.